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ABSTRACT 30 
One of the hallmarks of cancer cells is the increased ability to acquire nutrients, 31 
particularly glucose and glutamine. Proliferating cells need precursors for cell growth 32 
and NADPH reducing equivalents for survival. The principal responsible for glucose 33 
uptake is facilitative glucose transporters (GLUTs), which usually are overexpressed in 34 
cancer cells. Besides their role in glucose uptake, GLUT transporters are able to 35 
transport other compounds such as dehydroascorbic acid or uric acid. They play a major 36 
role in tumor progression and cellular processes such as regulated cell death. The 37 
prostate gland has the particular characteristic of being more glycolytic than other non-38 
pathological tissues given an accumulation of citrate in the seminal fluid and the 39 
inhibition of m-aconitase that affects to Tricarboxylic Acid Cycle. In prostate cancer 40 
(PCa), androgens increase glucose uptake, upregulate GLUT transporters such as 41 
GLUT1 and GLUT3 and stimulate AMPK pathway, suggesting a possible connection 42 
between glycolytic and androgenic signaling. Interestingly, diabetes is not a risk factor 43 
of PCa, as it is in other cancers, while insulin stimulates progression and IGF1 pathway 44 
plays an important role in PCa progression. It was recently found that PCa cells 45 
overexpress GLUT4 and, more importantly, that it seems to be related to the castration-46 
resistant phenotype, though little is known about its participation in tumor progression. 47 
This review will focus on the role of GLUT transporters along with PCa progression, 48 
and the involvement of GLUT4 on castration-resistant phenotype transition would be 49 
considered.   50 
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INTRODUCTION 51 
In the 20’s, Otto Warburg described a phenomenon in tumors that it was called 52 
the “Warburg effect”. This discovery took place even before ATP was discovered or 53 
glycolysis was formulated
1
.  It is based on the enhancement of lactate production 54 
because of the increment of glycolysis independently of oxygen concentration
2
. 55 
Although Warburg related this effect with defects in mitochondria of tumor cells, later 56 
studies showed that mitochondria were not altered in tumor tissues and the phenomenon 57 
was related to proliferation and growth
3
.  58 
The interest in cancer metabolism has increased during the last few years and not 59 
only for its self-importance but also for its connection with other signaling pathways
4
. 60 
Before being considered a hallmark of cancer in 2011 by Hanahan and Weinberg
5
, 61 
Kroemer and Poyssegeur suggested that all hallmarks of cancer have somehow relation 62 
with metabolism
6
. Recently, six hallmarks of cancer metabolism have been proposed by 63 
Pavlova and Thompson in 2016
7
. Metabolic alterations of cancer cells include an 64 
increased ability to acquire nutrients, assigned preferred metabolic pathways and 65 
alteration of differentiation pathways.  66 
The increase of glycolysis carries a higher glucose uptake by glucose 67 
transporters (GLUT)
8
. Therefore, GLUT levels are usually related to tumor progression. 68 
Although most cancers drive with the traditional Warburg effect, there are differences 69 
among them, including those concerning GLUT transporters. The prostate is 70 
metabolically unique since the differentiated tissue is glycolytic instead of oxidative. 71 
Prostate cancer (PCa) transformation involves a metabolic switch to oxidative 72 
phosphorylation (OXPHOS) then, later, in the advanced castration-resistant phenotype 73 
turns again to glycolytic
9,10
.    74 
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PROSTATE CANCER: AN HORMONE-SENSITIVE CANCER WITHOUT A 75 
DIAGNOSTIC BIOMARKER 76 
PCa is the most common malignancy among men and the second leading cause 77 
of cancer death
11
. In 2012, more than 1.1 million cases were recorded (data are taken 78 
from GLOBOCAN, the most recent statistics from WHO)
12
. This means an 8% of total 79 
new cancer cases and a 15% of all affecting in men. Its prevalence is higher in the west 80 
(about 68% of new cases) perhaps due to lifestyle and environmental factors. However, 81 
age and race are also well-recognized risk factors
13
. Despite high incidence, PCa is 82 
usually characterized by a slow growth and unpredictable outcome. PCa is a disease 83 
with a mixed origin, and the absence of a biomarker impedes to know how to anticipate 84 
the outcome of the disease.  85 
Still, Prostate Specific Antigen (PSA) screening is the only predictive method 86 
employed in the clinic. However, its levels are dependent, among others, of obesity or 87 
age, being not always reliable
14
. A potential alternative is Prostate Cancer Antigen 3 88 
(PCA3), overexpressed in primary PCa and metastases
15
. 89 
PCa is sensitive to hormones, mainly androgens. The active form of testosterone, 90 
dihydrotestosterone (DHT), mediates androgen receptor (AR) classical activation. 91 
Androgen responsive genes are involved in normal prostate architecture, homeostasis, 92 
and physiology but, in PCa, androgens promote proliferation and survival of cancer 93 
cells. Antihormonal therapy is, at first, a successful therapeutic approach
16
. However, 94 
PCa frequently becomes resistant to androgen deprivation, reaching a castration-95 
resistant (CRPC) phenotype difficult to handle.  96 
Contrary to other cancers, there is not a single pathway implicated in PCa 97 
progression nor a clear candidate as a biomarker. The homeobox gene HOXB13 was 98 
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found as a predisposition gene
17
. Also, seventy-seven single nucleotide polymorphisms 99 
close to a noncoding region of the oncogene c-MYC and with the capacity to alter its 100 
expression, are also considered a prognosis marker
14
. In the 90% of PCa, Glutathione-S-101 
transferase pi 1 gene (GSTP1) is hypermethylated, and it can be detected in urine
18
.  102 
More than half of the cases of PCa drive with androgen-driven ETS gene 103 
expression because of genomic rearrangements. However, ETS gene fusions need other 104 
events such as activation of PI3K/AKT pathway, which is mainly related to PTEN loss. 105 
Then, ETS-positive tumors are different from ETS-negative tumors, but PTEN and 106 
TP53 mutation occurs in both types
14
.  107 
In CRPC, there are additional oncogenic pathways involved. The RAS/MAPK 108 
pathway and TGF3 are upregulated in patients with metastatic CRPC. In addition to 109 
AR signaling, the WNT/-catenin and the Insulin-like growth factor (IGF) 1 pathways 110 
seem to play a major role in the most aggressive phenotype of CRPC
19
.  111 
Still, there is not a clear biomarker, as there is neither an effective treatment. 112 
Anti-hormonal therapies employed when cancer is still androgen-sensitive, and they go 113 
together with radiotherapy in localized or locally advanced carcinoma
16
. For CRPCs, 114 
docetaxel has been the preferred and the first-option chemotherapy during the last 115 
decade, but recent-discovered compounds have also been proposed as succesful
20
.  116 
Then, PCa is still a tumor without an effective prognostic and predictive 117 
biomarker and a curative treatment. However, targeting glucose metabolism has the 118 
potential to provide prognostic information and to treat PCa, since several glycolytic 119 
pathways are altered in the disease.   120 
THE CURIOUS CASE OF GLYCOLYTIC METABOLISM IN 121 
PROSTATE 122 
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In differentiated cells, glucose in the presence of oxygen is predominantly 123 
employed to get their energetic requirements from OXPHOS in mitochondria.  124 
However, under hypoxia, lactic glycolysis is favored rendering only two ATP molecules 125 
from one molecule of glucose, instead of the 36 molecules obtained by OXPHOS
21
. In 126 
cancer cells, and in other proliferative cells, the rates of glycolysis and lactate 127 
production are enhanced. Even in the presence of oxygen, cancer cells select for 128 
glycolysis instead of OXPHOS to metabolize glucose in a process called “aerobic 129 
glycolysis”3.  130 
Aerobic glycolysis favors glycolytic pathways to produce the building blocks 131 
necessary to cell growth. Several oncogenic signaling pathways promote aerobic 132 
glycolysis and the increase of lactate secretion
22
.  133 
PCa, like other tumors, progresses with molecular alterations that cause an 134 
increase in glucose, glutamine and lipid metabolism. However, PCa is characterized by 135 
a particular metabolism of glucose that differs from the rest of carcinomas.  136 
          The prostatic fluid contains high levels of citrate because of the inhibition of m-137 
aconitase, a tricarboxylic acid (TCA) cycle enzyme that converts citrate to isocitrate. 138 
This inhibition is driven by the overexpression of the zinc-regulated transporter/iron-139 
regulated transporter-like protein 1 (ZIP1) in prostatic epithelial cells. Since the TCA 140 
cycle is somehow compromised in the prostate gland, glycolysis is favored (Fig 1). 141 
During tumor transformation, ZIP1 levels decrease, and OXPHOS is promoted
9
. 142 
However, this may only happen during the first steps of carcinogenesis. One study 143 
shows that the mitochondrial content does not change during carcinogenesis, but 144 
OXPHOS decreases with invasiveness
23
.  145 
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Lactate production is usually associated with tumor progression in PCa. In 146 
addition to its catabolic products, pyruvate, and alanine, lactate measurement has been 147 
considered urine biomarker for non-invasive detection of PCa
24
. On the other hand, 148 
factors related to reverse Warburg effect were recently proposed as a marker to 149 
distinguish Gleason grades
25
. PCa cells employ interleukin-6 secretion to activate 150 
glycolysis in cancer associated fibroblasts, which, in turn, increase lactate secretion
26
. 151 
Lactate is consumed by OXPHOS-dependent PCa cells, having a role in redox 152 
homeostasis and angiogenesis
27
.  153 
 Glucose metabolism has not been considered as important as glutamine or lipid 154 
metabolism in PCa progression, being the reason why it has been less studied. Several 155 
candidates have been proposed as potential metabolic targets. Multiple studies are 156 
underway employing inhibitors of lipogenesis, cholesterol metabolism, and glutamine 157 
metabolism
28
. Recently, the upregulation of the steroid receptor coactivator 2 (SRC2), 158 
which drives glutamine-dependent de novo lipogenesis, was proposed as an important 159 
co-regulator for PCa survival and metastases
29
, and Sarcosine, an N-methyl derivative 160 
of glycine, is considered an important regulator of progression and metastases
30
.  161 
However, glucose metabolism in PCa is different to other tumors given their 162 
close relation to AR signaling. Glycolysis differs between androgen-sensitive and 163 
insensitive cells, being tumors more aggressive more glucose-dependent
31,32
. Also, AR 164 
regulates several genes that are closely related to glucose consumption and biomass 165 
production
33
. Thus, an increased activity of several glycolytic enzymes by androgens 166 
has been found. Hexokinase-2 (HKII) phosphorylation is stimulated by androgens via 167 
protein kinase A signaling while 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 168 
2 (PFKFB2) is stimulated by direct binding of AR to PFKFB2 promoter. Activation of 169 
PFKFB2 causes a constitutive activation of 6-phosphofructo-2-kinase (PFK2), which is 170 
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involved in the second irreversible reaction of the glycolytic pathway
34
. Another 171 
isoform of PFK2, PFKFB4, was considered an important regulator for PCa survival
35
. 172 
HKII is also involved in the increase of glucose metabolism after androgen deprivation 173 
in PTEN/Tumor protein p53 (TP53) deficient PCa cells
36
. Thus, HK inhibitors such as 174 
3-bromopyruvate or ionidamine are being tested in clinical trials
37
. Moreover, Pentose 175 
Phosphate Pathway (PPP) is promoted by an AR-mTOR mediated mechanism, 176 
maintaining Glucose-6-phosphate dehydrogenase (G6PDH) levels higher during PCa 177 
progression
38
. Overall, androgen signaling stimulates both glycolysis and anabolic 178 
metabolism  179 
Androgens positively regulate glycolysis via Calcium/calmodulin-dependent 180 
protein kinase kinase beta (CamKKβ), which activates AMP-activated protein kinase 181 
(AMPK)
39
. AMPK is a metabolic regulator that promotes migration, cell growth and 182 
survival of PCa cells
40,41
. Because of AMPK activation, androgens activates peroxisome 183 
proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), which is connected 184 
with mitochondrial biogenesis (Fig 2). Although PGC1α is overexpressed in patient 185 
samples, it was proposed as an antimetastatic factor
42
. Since PGC1α favors an oxidative 186 
metabolism, its loss could be related to the acquisition of a glycolytic and more 187 
aggressive phenotype
43
.  188 
Interestingly, high blood glucose drives with low levels of AR
44
. Thus, this 189 
might explain the surprising inverse relation between diabetes and PCa that will be 190 
discussed below. 191 
ARE GLUT SUFFICIENT TO SUPPORT PROSTATE CANCER 192 
GROWTH AND SURVIVAL? 193 
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Since cancer cells show a high demand for nutrients for cell growth, the uptake 194 
has to be higher. In non-pathological tissues, cells become quiescent when the resources 195 
are scarce, but cancer cells lose this control, being always addicted to nutrients. 196 
Principal nutrients are glucose and glutamine
3
.  197 
There are two different types of transporters for glucose: Na
+
/glucose 198 
transporters (SGLTs, SLC5A) and facilitative glucose transporters (GLUTs, SCL2A). 199 
Among the 12 members of SGLTs, only SGLT1 and SGLT2 are proposed as 200 
responsible for glucose uptake in some cancer cells
45
.  201 
GLUT transporters internalize glucose by a mechanism of facilitated diffusion. 202 
There are 14 members (GLUT1-12, GLUT14 and H
+
/myo-inositol transporter –HMIT-203 
). They transport other compounds in addition to glucose, and that circumstance 204 
establishes the differences between members. They also differ in their affinity for 205 
substrate and tissue location. They are divided into three classes: Class I includes 206 
GLUT1-4 and GLUT14, class II are GLUT5, GLUT7, GLUT9 and GLUT11 and class 207 
III consist of GLUT6, GLUT8, GLUT10, GLUT12, and HMIT. Class I is the best 208 
characterized, and its members share the same bacterial ancestor –XylE-46. Class II is 209 
able to transport fructose and, class III is structurally different. They share common 210 
elements as 12 transmembrane -helixes while the cytoplasmic N-terminus and C-211 
terminus are less conserved among members
47
.  212 
 GLUT transporters respond to metabolic and hormonal regulation, and several 213 
transcription factors are able to increase glucose uptake by overexpressing or locating 214 
GLUTs on the cell membrane. Furthermore, under hypoxia or nutrient deprivation, 215 
tumor cells overexpress at least one of the isoforms, being predominantly GLUT1
48
. 216 
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GLUT1 is overexpressed under growth factor withdrawal, which makes cancer cells 217 
more resistant to apoptosis
49
.    218 
GLUT transporters are regulated by glycosylation or phosphorylation. It was 219 
well studied that GLUT transporters are N-glycosylated, which is associated with its 220 
ability to increase glucose uptake
50,51
. Phosphorylation was recently described, opening 221 
a new paradigm of GLUT regulation. It was shown a phosphorylation site at serine 490 222 
for ataxia telangiectasia mutated (ATM) that promotes surface GLUT1
52
 and at serine 223 
226 for protein kinase C which is related with GLUT1 deficiency syndrome
53
.  224 
The important role of GLUT transporters is also linked to the uptake of other 225 
compounds than glucose. The best well known is dehydroascorbic acid
54
, the oxidized 226 
form of vitamin C, and recently our group opens the possibility that melatonin might 227 
also enter into the cell via GLUT transporters
55
. The affinity for the different substrates 228 
can be dependent on the interaction of other transmembrane proteins
56,57
.  229 
GLUT1 is usually associated with poor prognosis in tumors
58
. However, not 230 
always this transporter is found overexpressed in cancer, and other GLUTs are instead 231 
involved in increasing glucose uptake
8
. GLUT-dependent glucose uptake has an 232 
important role in diagnosis by positron emission tomography (PET) imaging. The 233 
uptake of 2-deoxy-2-[
18
F]-fluoro-D-glucose (
18
F-FDG) is employed in PET to follow 234 
glucose uptake. This compound is phosphorylated by hexokinase (
18
F-FDG-6P), but it 235 
cannot continue the glycolytic pathway, being accumulated into the cytoplasm. This 236 
methodology is valid as a diagnostic tool particularly when cancer drives with the 237 
classical Warburg effect
59
.  238 
GLUT TRANSPORTERS AS CLINICAL TARGETS IN PROSTATE CANCER 239 
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In diagnosis, classic 
18
F-FDG-PET has not been considered useful in primary 240 
PCa tumors, so the increased glycolysis and GLUT overexpression have not been 241 
recognized as relevant as in other tumors. However, now it is assumed that its utility is 242 
dependent on the stage of the disease. Also, the high activity by urine in the adjacent 243 
urine bladder overlaps the signal in prostate
60
. Thus, the assumption that 
18
F-FDG-PET 244 
is not valid because PCa is not a glycolytic carcinoma should be discarded. 245 
In PCa, it seems that exists a possible balance among GLUT transporters, being 246 
the majority-produced transporter dependent of the step of the disease (Table 1). 247 
GLUT1 is found overexpressed in PCa cells, being the highest levels found in 248 
androgen-independent cells
32
. Since GLUT1 is usually the transporter overexpressed in 249 
tumors, it has been the most studied in PCa. Although higher GLUT1 levels were also 250 
found in non-tumor tissues
61
, it seems that GLUT1 is related to aggressiveness because 251 
it is usually overexpressed in poorly differentiated tumours
62
. Also, GLUT1 is 252 
connected with recurrence after radical prostatectomy
63
. This overexpression seems to 253 
be dependent of hypoxia more than androgenic regulation. Also, the stromal levels of 254 
GLUT1 have been employed to classified PCa by Gleason score and to indicate the 255 
presence of a tumor area undetected by biopsia
25
. Furthermore, GLUT1 is involved in 256 
the increase of glucose uptake by inflammatory cells in PCa
64
 and it was recently 257 
described that GLUT1 overexpression in PCa might be mediated by the reduced levels 258 
of microRNA-132
65
. Regarding its intracellular localization, GLUT1 was also found in 259 
Golgi Apparatus where it could have a role in supplying glucose to the prostatic fluid
66
.  260 
On the other hand, GLUT3 is activated via caveolin-1 in AR-negative cells
67
 261 
and GLUT12, which is also considered an insulin-dependent transporter, was found in 262 
PCa but not in non-tumor samples
66
, suggesting a similar role than other insulin 263 
dependent transporters as GLUT4 in tumorigenesis.  264 
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Fructose consumption in the modern diet is increasing, and it is considered a 265 
cancer risk factor. In tumor cells, fructose is differently metabolized than glucose, being 266 
mainly employed for nucleic acid synthesis
68
. However, in PCa, fructose was not 267 
considered as a risk of metastasis
69
. Fructose is secreted in seminal vesicle, so high 268 
concentration is found in the dorsal prostate and coagulating glands (rodent anatomy)
70
. 269 
GLUT5, the main fructose transporter in addition to GLUT2, is produced in the apical 270 
membrane of secretory cells in normal tissue and high-grade intraepithelial neoplasia 271 
(HGPIN). Furthermore, SLC2A7, SLC2A9, and SCL2A11 mRNAs were found in PCa 272 
but only SCL2A11 mRNA levels increased in PCa tissue respect benign prostate
61
. 273 
Altogether, fructose uptake might have a role in PCa progression, particularly at early 274 
stages.  275 
In PCa cells, androgen stimulation increases both GLUT1 and GLUT3, 276 
increasing glucose uptake and the secretion of lactate
71
. However, these transporters, 277 
particularly GLUT1, are downregulated by DHT in non-tumor Sertoli cells
72
. Thus, 278 
hormonal regulation of GLUT1/3 seems to be tissue-dependent.  279 
Interestingly, androgens and antiandrogens are able to interact with GLUT1 at 280 
the external opening since GLUT1 and the ligand-binding domain of AR share 281 
sequence homologies
73
, establishing the idea that regulation is not only via signaling 282 
pathway. Other members such as the fructose transporter GLUT5 also seems to be 283 
under androgenic regulation. Using the antiandrogenic flutamide in Scotophilus healthy, 284 
GLUT5 production is reduced in testis
74
. 285 
As previously discussed, androgen signaling activates AMPK. As a metabolic 286 
regulator, AMPK regulates GLUT transporters
75
. Activated AMPK inhibits activation 287 
of thioredoxin-interacting protein (TXNIP), which binds to GLUT1 avoiding its 288 
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expression and translocation (Fig 2)
76
. Consequently, the insulin-independent GLUT1, 289 
and consequently glucose uptake, is also hormonal regulated. 290 
Besides AMPK, PI3K/AKT/mTOR pathway has a major role in glucose 291 
metabolism through its activation by insulin and IGF1. AKT1 stimulates glycolysis by 292 
an increase in both the expression and translocation of GLUT transporters in addition to 293 
the phosphorylation of glycolytic enzymes such as hexokinase and 294 
phosphofructokinase
8,77
. On the other hand, PTEN, the inhibitor of PI3K/AKT pathway, 295 
is able to reduce SLC2A1 expression directly
78
.  296 
Hypoxia-inducible factors HIF1 and HIF2 are involved in the cellular response 297 
to low oxygen concentration in PCa
79
. HIF1 promotes the transcription of the majority 298 
of glycolytic enzymes and GLUT transporters, mainly GLUT1 and GLUT3
8
.  299 
KRAS is frequently mutated in PCa, and its rearrangements were mainly 300 
involved in metastases
80,81
. Tumors with mutations in this gene drive with an increasing 301 
rate of glycolysis and higher use of glycolytic products in other anabolic pathways
82
. 302 
Mutation of KRAS and BRAF are related with GLUT1 overexpression in cancer
83
.  303 
TP53, known as “genome guardian” has a dual role in glucose metabolism. On 304 
the one hand, it activates HKII expression but, on the other hand, it inhibits glycolysis 305 
by the overexpression of TP53-inducible glycolysis and apoptosis regulator TIGAR
84
. 306 
TP53 reduces SLC2A1 and SLC2A4 transcription
85
, and it interacts with SLC2A12
86
. On 307 
the other hand, the loss of TP53 upregulates GLUT3
87
. P53 mutations are usually found 308 
in PCa and as a consequence, a higher expression of GLUT transporters was 309 
described
88
.  310 
Since the inhibition of glycolysis by 2DG (2-deoxyglucose) causes an 311 
activation of autophagy in patients with CRPC, its use in the clinic has to be considered 312 
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in combination with autophagy inhibitors
89,90
. Then, targeting glucose metabolism could 313 
be an option to treat PCa. However, consulting the current clinical trials in prostate 314 
(data are taken from www.clinicaltrials.gov), only 1% has a direct association with 315 
glucose metabolism, being one directly related with GLUT transporters (Fig 3).  316 
Nevertheless, most studies are focused on inhibiting glucose uptake by 317 
blocking GLUT transporters. Currently, the recent crystallization of GLUT transporters, 318 
the better knowledge of the mechanism of inhibition and the development of GLUT-319 
specific inhibitors open a new approach for the treatment of cancer that develops with 320 
increasing glucose uptake. Glucose deprivation kills cancer cells by different 321 
mechanisms
91
. The consequences of blocking glucose transporters, besides the 322 
downregulation of glycolysis, are the inhibition of cell growth, cell cycle arrest and 323 
FAS-induced cell death
92,93
. In fact, fasentin, a compound that inhibits GLUT1, 324 
increases apoptosis by sensitizing cells to FAS-ligand death receptor signaling in PCa 325 
cells
94
. 326 
Although there are not clinical trials focused on specific compounds that block 327 
GLUTs in PCa, some compounds that inhibit progression are well-known blockers of 328 
GLUT transport, particularly flavonoids. They play an important role in PCa prevention 329 
since their phytoestrogen activity and have a promising application as adjuvant 330 
treatment
95
. 331 
THE INSULIN-DEPENDENT GLUT4 TRANSPORTER IN PROSTATE 332 
CANCER: A LINK BETWEEN DIABETES AND PROSTATE CANCER? 333 
Although the insulin-dependent glucose transporter GLUT4 has not been 334 
considered as important as GLUT1 in cancer, recent studies show the critical role that 335 
might play in several types of tumors. This transporter was described by our group in 336 
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PCa culture cells
96
 for the first time. We found that phytoestrogens regulate GLUT1
96
 in 337 
androgen sensitive LNCaP cells GLUT4 in androgen-insensitive PCa cells while 338 
showing a possible balance between both transporters dependent on the phenotype of 339 
the cells. We have found an increase production of GLUT4 by androgen-insensitive 340 
cells (unpublished data). In fact, GLUT4 has been already detected in the prostate of 341 
Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice
97
. However, in this 342 
model, the relevance of GLUT4 in tumor progression is under investigation.  343 
It has been described that testosterone stimulates GLUT4-dependent glucose 344 
uptake in human skeletal muscle cells, cardiomyocytes, and 3T3-L1 adipocytes 345 
independently of AR signaling
98–101
. In adipocytes, it was confirmed that this regulation 346 
occurs through Liver kinase B1 (LKB1)/AMPK signaling. As previously described, 347 
AMPK phosphorylates the Rab-GTPase TBC1D1, which triggers GLUT4 348 
externalization
102
. On the other hand, endometrial GLUT4 levels decrease after DHT 349 
treatment, and they are inversely related to AR expression in polycystic ovary 350 
syndrome
103
.  351 
Since GLUT4 is regulated by androgen-independent mechanisms in other 352 
tissues, its regulation in PCa might not be dependent on androgens or AMPK signaling. 353 
On the other hand, IGF1/insulin pathway regulates insulin-dependent transporter, which 354 
suggests its possible role in the regulation of GLUT4 in PCa. In this sense, it implies 355 
that this transporter could be more relevant in androgen-insensitive phenotype as our 356 
group previously suggested. In addition, GLUT4 might be an intermediate in the effect 357 
of insulin on PCa and might have some role in the inverse relationship between diabetes 358 
and PCa.  359 
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PCa risk is related to lifestyle being high-fat diet connected to its progression 360 
and aggressiveness. Hyperinsulinemia, which is usually associated with insulin 361 
resistance, is also related with a higher PCa risk
104–106
. Interestedly, insulin levels are 362 
higher in PCa patients
107
, and insulin receptors (IR) have been found in PCa epithelial 363 
cells
108
. Moreover, epidemiological studies show a significantly decreased risk of PCa 364 
in long-standing type 2 diabetes (T2DM)
109
. However, it has also been reported that 365 
diabetic men have a more aggressive PCa but their PSA levels remain low, avoiding its 366 
early detection
110
. 367 
Circulating insulin and testosterone levels are correlated in male
111
. On the one 368 
hand, higher insulin levels decrease the production of sex-hormone binding globulin 369 
(SHBG), increasing free and biologically active testosterone
112,113
. Moreover, the sex 370 
hormone promotes insulin production in beta-cells by the extranuclear activity of AR
114
 371 
(Fig 4A). Since this positive feedback, insulin signaling would be related to androgen 372 
promotion of tumor growth. However, the IGF1 pathway is usually overexpressed in 373 
PCa and, this pathway promotes AR hormone-independent activation which supports a 374 
role of insulin-dependent glucose transporters, as GLUT4, in androgen-independent 375 
tumor growth (Fig 4B).  376 
Under hyperinsulinemia, T2DM is usually treated using metformin, which 377 
activates AMPK in the liver
115
. Most of the current clinical trials connecting glucose 378 
metabolism and PCa are focusing on the treatment with metformin in androgen 379 
deprivation therapy. In several cancers, metformin itself is being considered a potential 380 
treatment. Since metformin inhibits the mitochondrial complex I, it was reported a 381 
metabolic switch towards glutamine metabolism in PCa
116
. However, it was shown that 382 
metformin induces apoptosis in the presence of other compounds such as the 383 
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antiglycolytic 2DG
117
 or the anti-androgen bicalutamide
118
, and it is particularly 384 
effective in CRPC
119
. Interestingly, metformin also inhibits androgen-induced IGF1 385 
receptor (IGF1R) overexpression
120
 so that GLUT4 transporter might be altered by this 386 
treatment.    387 
CONCLUDING REMARKS 388 
After almost 100 years, the metabolic switch to aerobic glycolysis is still under 389 
study in oncology. This change is accepted in most of the cancers, but PCa has been 390 
considered particular from the metabolic point of view because the role of glucose 391 
metabolism in the first steps of progression was less important. Now, several studies are 392 
showing that glucose metabolism plays an important role also in prostate carcinogenesis 393 
but in a different way than in the rest of cancers. Androgens, despite increasing 394 
glycolysis, are involved in anabolism promoting PPP and mitochondrial biogenesis. 395 
Thus, androgen dependent tumors are oxidative at first, shifting to glycolysis only in the 396 
latest stages of the disease. Then, contrary to other tumors, glucose transporters, and in 397 
particular GLUT1, are only overexpressed in the most aggressive tumors that usually 398 
drive with hypoxia and with a higher glycolytic activity (Fig 5). Since insulin signaling 399 
is related to PCa progression, it seems possible that insulin-dependent glucose 400 
transporters might play a relevant role in the progression of the disease. A role of 401 
insulin in PCa cancer is suggested by clinical observation since diabetes is inversely 402 
related to PCa and some clinical trials are ongoing using the antidiabetic metformin. 403 
This could be a good reason to look into the possibility of insulin-dependent glucose 404 
transporters act as principal players in those stages of the disease that do not depend on 405 
androgens. Glucose transporters have not been considered relevant in prostate cancer 406 
progression because glucose metabolism is different in prostate gland than in other 407 
differentiate tissues. However, the importance of these transporters has been recently 408 
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considered since the relevance of increasing nutrients uptake including glucose is 409 
clearly demonstrated in prostate cancer. From now on, the employment of components 410 
of glucose metabolism, including metabolites, enzymes or transporters to characterize 411 
carcinomas will be an area of interest that should be exploited and carefully considered.  412 
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 FIGURE LEGENDS 809 
Figure 1: Zn accumulation in the mitochondria of non-malignant prostatic 810 
epithelial cells. High Zn uptake in prostatic epithelial cells is due to the overexpression 811 
of ZIP1. Zinc is accumulated in mitochondria where it inhibits aconitase, TCA-cycle 812 
enzyme that converts citrate to isocitrate. Citrate excess is secreted into the prostatic 813 
fluid.  814 
Figure 2: Androgen regulation of AMPK in prostate cancer cells. 815 
Androgen stimulation activates CAMKKwhich phosphorylates AMPK. AMPK is 816 
responsible for promoting glucose uptake via GLUT1, glycolysis, and mitochondrial 817 
biogenesis in PCa cells.  818 
Figure 3: Clinical trials related to glucose metabolism in prostate cancer. 819 
(A) Number of clinical trials focused on metabolism and glucose metabolism in cancer 820 
and, particularly, in prostate cancer. (B) Number of current clinical trials (recruiting and 821 
active) focused on metabolism and glucose metabolism in cancer and, particularly, in 822 
prostate cancer. 823 
 
Table 1: Expression of GLUT transporters in non-malignant and tumor prostate 
Glucose 
transporter 
  Expression in prostate  Location 
 References 
GLUT1   Non-malignant prostate/Aggressive tumors  
Plasma membrane, cytoplasm, 
Golgi system. 
Secretory and luminal epithelial 
cells/Basal cells 
 
61,62,63,66 
GLUT3   CRPC    7 
GLUT4   PCa  Plasma membrane, cytoplasm  97 
GLUT5   
Non-malignant prostate/ Overexpression in 
HGPIN 
 
Plasma membrane (apical zone of 
epithelial cells) 
 
61 
GLUT7   
Non-malignant prostate/ Overexpression in 
PCa (mRNA levels) 
  
 
61 
GLUT9   
Non-malignant prostate/PCa without 
overexpression (mRNA levels) 
  
 
61 
GLUT11   
Non-malignant prostate/PCa with 
overexpression (mRNA levels) 
  
 
61 
GLUT12   PCa  Plasma membrane, cytoplasm  66 
 
Page 37 of 40 
 
Figure 4: Possible molecular pathways regulated by insulin in prostate 824 
cancer. (A) Positive feedback regulation between insulin and testosterone. Since insulin 825 
reduces SHBG synthesis in the liver, circulating active testosterone levels increase and 826 
stimulates insulin release by beta-cells in pancreas via extranuclear AR activity (B) 827 
Insulin stimulates testosterone production, which may activate AR signaling, and 828 
activates PI3K/AKT pathway by itself or through IGF pathway. This last activation 829 
might lead GLUT4 regulation in PCa cells. SHBG = Sex-hormone binding globulin. 830 
Test =Testosterone.  831 
Figure 5: Tumor progression in prostate and GLUT expression along it. 832 
The non-pathological prostate is characterized by high glycolytic activity and GLUT1 833 
expression because of impairment in TCA cycle. In the first stages of tumorigenesis, 834 
OXPHOS is favored, and circulating insulin levels increase in comparison with the non-835 
tumorogenic prostate. This may be connected with the expression of the insulin-836 
dependent transporter GLUT4. In poorly differentiated PCa tumors, glycolysis and 837 
GLUT1 overexpression are again promoted, being correlated with low oxygen levels.  838 
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